Cost-effectiveness analysis of second intravenous immunoglobulin infusion versus infliximab for treating IVIG-resistant Kawasaki disease patients
Paediatrics
Cost-effectiveness analysis of second intravenous immunoglobulin infusion versus infliximab for treating IVIG-resistant Kawasaki disease patients
Paediatrics

Cost-effectiveness analysis of second intravenous immunoglobulin infusion versus infliximab for treating IVIG-resistant Kawasaki disease patients

Cost Eff Resour Alloc. 2025 Nov 22. doi: 10.1186/s12962-025-00674-0. Online ahead of print.

NO ABSTRACT

PMID:41275214 | DOI:10.1186/s12962-025-00674-0